FDA approves first CAR-T cell therapy for multiple myeloma
Bio Pharma Dive
MARCH 27, 2021
Approval of Bristol Myers Squibb and Bluebird bio's Abecma expands use of CAR-T treatment beyond leukemia and lymphoma.
Sat.Mar 27, 2021 - Fri.Apr 02, 2021
362 
Should doctors refuse to treat obese patients?
World of DTC Marketing
MARCH 28, 2021
IN BRIEF: Doctors are not required to treat obese patients who won’t do anything to lose weight but the problem is more than reminding patients they need to get exercise and drop pounds. One study found that only 50 percent of patients follow the instructions associated with taking their medication, and even fewer implement necessary lifestyle changes suggested by their doctor.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Caribou Biosciences is Armoring Cells to Fight Disease Through CRISPR
BioSpace
MARCH 28, 2021
The company’s overarching aim is to edit and equip cells with molecular tools, through CRISPR, to eliminate certain cancers.
Azelis releases ‘Action 2025’, confirming sustainability as a key driver in growth strategy
Pharma Mirror
MARCH 31, 2021
Azelis, an innovation service provider, is excited to release its sustainability strategy, ‘Action 2025’, reinforcing its commitment to become the world-leading provider of sustainable solutions and services in the specialty chemicals and food ingredients distribution industry. Through its sustainability program and strategy, Azelis wants to turn the sustainability aspirations of its principals and customers into innovative sustainable solutions.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
5 FDA approval decisions to watch in the second quarter
Bio Pharma Dive
MARCH 29, 2021
A long-awaited reckoning for Biogen’s Alzheimer’s drug and the review of AstraZeneca’s coronavirus vaccine are among the top FDA decisions expected before the end of June.
What’s the call to action on DTC?
World of DTC Marketing
MARCH 29, 2021
TEASER: What DTC marketers and consumers do as the result of seeing a relevant DTC ad differs by a wide margin. DTC marketers would like to think that patients ask for the advertised drug when visiting their doctor, but that’s largely untrue. Online searches for health information remain brisk, according to Google. Many people are going online for health information as the Internet has become cluttered with misinformation.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
CPhI Discover: connecting global pharma & pre-qualifying partners ahead of in person events
Pharma Mirror
MARCH 31, 2021
Informa Markets is launching an annual dedicated online platform for pharma in May (17-28th), CPhI Discover – designed to encourage suppliers and customers to source, meet and discover – providing the industry with a new synergistic offering to sit alongside CPhI’s portfolio of in person events. In the last year, the pharma industry has adapted its approach to meeting new partners and existing customers, with wider pools of suppliers now needed, putting greater pressure on resources to find and
A year with COVID-19: The impact of data on pharma marketing
Bio Pharma Dive
MARCH 29, 2021
Learn how three pharma brands used data to validate and adjust their promotional spend in 2020.
Personal responsibility in our healthcare
World of DTC Marketing
APRIL 1, 2021
IN BRIEF: At some point, we need to realize that good health is our personal responsibility. All prescription drugs don’t make us healthy; they just mask a potentially unhealthy lifestyle that eventually will cost patients and our healthcare system a lot of money, time, and pain. Responsibility for health should be a collaborative effort among individuals and the societies in which they live.
Lilly and GSK/Vir antibody pairing offers resistant COVID-19 hope
pharmaphorum
MARCH 30, 2021
Two antibodies targeting different parts of the COVID-19 virus spike protein, from Eli Lilly and GlaxoSmithKline/Vir Biotech, can cut viral load dramatically within a week. . The BLAZE-4 trial found that co-administration of Lilly’s bamlanivimab – already granted emergency approval as a COVID-19 treatment – and GSK/Vir’s experimental antibody VIR-7831 reduced virus levels by 70% after seven days compared to placebo in people with mild or moderate COVID-19 symptoms.
Pfizer and BioNTech ramp up COVID-19 vaccine production to 2.5 billion doses
BioPharma Reporter
MARCH 31, 2021
Pfizer and BioNTech expect to expand COVID-19 vaccine manufacturing capacity to up to 2.5 billion doses by the end of 2021, thanks to the optimization of production processes and the recent initiation of production in Marburg, Germany.
FDA advisers reassert case against approval of Biogen's Alzheimer's drug
Bio Pharma Dive
MARCH 31, 2021
In a new editorial, three of the agency's advisers reiterated that they see "no persuasive evidence to support approval of aducanumab at this time.
Allocating DTC budgets
World of DTC Marketing
MARCH 30, 2021
I N BRIEF : DTC managers usually have a tough time allocating DTC budgets, but once you layout your brand objectives and better understand your audience, the choices become clearer. Learn everything you can about your audience, such as “where are they online and what are they really looking for in treatment options?” The budgeting process is over, and as a DTC manager, you need to decide how much of your budget goes in each bucket.
NHS extends ‘COVID-friendly’ at-home cancer care
Pharma Times
MARCH 31, 2021
Funding for effective, 'less risky' treatments extended until summer 2021
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Global Vaccine Passports Edge Closer, Speeding Arrival of the Next “Normal”
BioSpace
MARCH 30, 2021
Vaccine passports are an interim step that can speed the return of some semblance of normality by allowing the rapidly growing numbers of vaccinated people to travel more easily and to attend typically crowded sporting events, concerts and religious services.
Pfizer vaccine data show durable protection, hint at efficacy against virus variant
Bio Pharma Dive
APRIL 1, 2021
Updated Phase 3 study results could position Pfizer to file for full approval of its vaccine and might have implications for its plans to develop a booster shot.
Germany and Canada restrict AZ vaccine again over blood clot fears
pharmaphorum
MARCH 31, 2021
Germany and Canada have both slapped restrictions on the AstraZeneca vaccine, recommending its use only in older patients, because of concerns over a link with blood clots. The moves come after the country’s medicines regulator found 31 cases of a rare type of blood clot known as cerebral venous sinus thrombosis (CVST) in people who had received the vaccine produced by AZ.
Cytiva diagnostics design lab goes live in China
BioPharma Reporter
MARCH 29, 2021
Cytiva has opened a new diagnostics design lab in Tonglu, its manufacturing site close to Shanghai in East China, where it has been making filtration products for many years.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
After About 50 Years, the mRNA Revolution is Here
BioSpace
MARCH 30, 2021
Between the Moderna and Pfizer-BioNTech COVID-19 vaccines, there are two mRNA therapeutics on the market … the only two.
A biotech shelves its Huntington's drugs after trial failures
Bio Pharma Dive
MARCH 30, 2021
Two drugs developed by Wave Life Sciences didn't appear to have an effect on disease-causing proteins, another setback for Huntington's research after disappointing results last week from Roche and Ionis.
Alexion’s Camilla Harder Hartvig on making the impossible possible in rare disease
pharmaphorum
MARCH 30, 2021
Alexion’s senior vice president of its international business talks to Paul Tunnah about the importance of “people-centred and vulnerable” leadership, the surprising impacts of COVID and the promising future for treating patients with rare diseases. . Alexion is a somewhat unique pharma company in that it focuses almost entirely on rare diseases – and although this is an immensely challenging area to operate in, the company’s senior vice president of its international business, Camilla Harder Ha
Novartis UK signs digital partnership with Cievert for chronic disease management
Pharma Times
MARCH 29, 2021
Initiative is aiming to support NHS patient care in rheumatology and dermatology
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Is Electrolyte Beer the Next Big Beverage Trend?
XTalks
APRIL 1, 2021
There is no shortage of post-workout drinks on the market, including innovative new additions to the category, like high-protein chocolate milk to sports drinks made with upcycled dairy byproducts. But could an electrolyte beer be just the thing to quench consumers’ thirst after a session at the gym? A few breweries in the US are trying to make that a reality with low alcohol by volume (ABV) beers infused with electrolytes and other nutrients.
Manufacturing mix-up could blunt supply boost from J&J vaccine
Bio Pharma Dive
APRIL 1, 2021
One vaccine batch being manufactured for J&J by Emergent Biosolutions failed quality checks, reportedly ruining material sufficient for up to 15 million doses.
Akili’s gaming therapy improves attention in ADHD kids
pharmaphorum
MARCH 29, 2021
Akili has published data backing the efficacy of its childhood attention-deficit hyperactivity disorder (ADHD) video game therapy EndeavorRx in the peer-review journal Nature Digital Medicine. . The results come from the STARS-Adjunct trial, an open-label study of EndeavorRx (AKL-T01) that supported approval of the app and video game combination in the US and Europe last year.
EU approval for new AI technology that can predict heart attacks
Pharma Times
MARCH 30, 2021
CaRi-Heart technology can identify people at high risk of a fatal heart attack
AI algorithm automates analysis of cystic fibrosis scans
Outsourcing Pharma
MARCH 30, 2021
Artificial intelligence software company Thirona has released PRAGMA-AI, technology that automates and accelerates CT scans in cystic fibrosis analysis.
UniQure says hemophilia gene therapy likely not cause of study volunteer's cancer
Bio Pharma Dive
MARCH 29, 2021
The determination, made by UniQure and an independent lab, could ease safety concerns spurred by the patient's diagnosis in December.
How Long Will COVID-19 Vaccines Be Effective? Six Months and Counting
BioSpace
APRIL 2, 2021
A current Phase III trial of the Pfizer-BioNTech COVID-19 vaccine has confirmed the protection remains high for at least six months after the second dose. In a statement, Pfizer and BioNTech reported the vaccine was 91.3% effective against the disease.
Inctye’s Pemazyre authorised in the EU for bile duct cancer
Pharma Times
MARCH 30, 2021
Kinase inhibitor authorised to treat advanced bile duct cancer patients with a FGFR2 fusion or rearrangement
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Let's personalize your content